The funding round was led by the Development Bank of Wales with participation from angel investors and Parkwalk.
Funding Announcements
Filter
Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
238
Total raised
£3.1B
disclosed amounts
This month
£7.8M
raised so far
£575K
£7.7M
Signifier Medical Technologies raises £7.7m in a Series C round led by Alan Howard to advance sleep disorder treatments
Alan Howard led the Series C round, with participation from James Blair and The Pritzker Organization.
"I look for companies that are addressing extensive market opportunities, are rapidly growing, and have experienced leadership teams. I strongly believe Signifier is one of those companies, and I am pleased to support its transformational innovation to address sleep and breathing disorders and chronic care management."
£500K
CMS Ventures has backed the Cambridge clinical analytics start-up in its latest funding round.
"This investment will allow us to grow our team and capitalise on recent partnerships in industry to analyse upcoming clinical trial data in a number of respiratory diseases. Crucially, it will allow us to launch the next iteration of our platform to deeper integrate with large data sets. We are really excited that CMS Ventures has decided to join us on the journey as we scale the company. By unlocking the data from an individual patient journey, we will be able to help many others with the same diseases."
£100K
Inovus Medical secures £100k in grant funding from the LCR Future Innovation Fund to accelerate international expansion.

The Liverpool City Region initiative has backed the surgical simulator developer with £100k to drive overseas exports and scale manufacturing.
£790K
The Oxford startup raised the capital from Microsoft's venture fund and Mayfield following its success in the Female Founders Competition.
"We are so excited to name iLoF a winner of the Female Founders Competition and invest $1 million alongside Mayfield. iLoF’s technology promises to create effective treatments tailored for the individual, which will change healthcare trajectories for millions of people living with complex disorders. Their mission is humbling, and we are thrilled to support this company with our investment and as a board observer."



